HCPCS Level II code P7001 denotes a quantitative bacterial urine culture with antimicrobial sensitivity testing, a commonly ordered microbiology diagnostic that guides treatment for suspected urinary tract infections and septic evaluations. Nationally, urine culture with susceptibility is a key component of laboratory services used across inpatient and outpatient settings to support appropriate antimicrobial selection and infection management.

Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context and service setting for P7001, plus what to expect from payer coverage patterns and common billing considerations. The publication highlights benchmarks related to utilization and reimbursement trends, summarizes relevant policy updates affecting laboratory services, and situates P7001 within typical clinical workflows (specimen collection, laboratory processing, and reporting of susceptibility results).

The content is intended for billing managers, laboratory directors, and policy analysts seeking a national perspective on how this laboratory procedure is coded and processed. Data not available in the input where specific payer policies, associated taxonomies, ICD-10 diagnoses, and related codes would normally be summarized.